Also keep in mind that once Leronlimab is validated by an approval for Covid you remove a lot of the doubt about what is possible. Excellent Covid results will lend weight to our (so far) small number of cancer results. Other indications will look less like throwing a bunch of ideas against a wall hoping one will stick and look more like a high probability line extension as a result of a proven mechanism of action. My prediction (total gut call) is we uplist, sign an agreement or three with banks/distributors, nearing $10 before approval. After approval we triple or quadruple into the $30’s.